echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Effect of DS-1001 in the treatment of relapsed/progressive IDH1 mutant gliomas

    Effect of DS-1001 in the treatment of relapsed/progressive IDH1 mutant gliomas

    • Last Update: 2022-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Atsushi Natsume et al.



    ——Excerpt from the article chapter


    【Ref: Natsume A, et al.



    Research background

    About 70% of low-grade gliomas have isotrate dehydrogenase 1 (IDH1) mutations, resulting in the accumulation of the tumor metabolite D-2-hydroxyglutaric acid (D-2HG), prompting glioma progression, epigenetic disorders, and further clonal amplification




    The DS-1001 study for the treatment of relapsed/progressive IDH1-R132 mutant gliomas was a multicenter, open-label, and dose-escalating phase I trial



    Research results

    The therapeutic dose in the trial did not reach the maximum tolerated dose



    The results show that patients with recurrent/progressive IDH1-R132 mutant glioma have good tolerance to DS-1001, can efficiently cross the blood-brain barrier, and have a good effect




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.